BIORA THERAPEUTICS, INC.: Nasdaq/NYSE listing notice — Biora Therapeutics receives Nasdaq notice of non-compliance with MVLS minimum $50M requirement

BIORA THERAPEUTICS, INC.

Received Nasdaq notification on Dec 11, 2023 that MVLS was below $50M for 30 consecutive business days.
Company has 180 calendar days, until June 10, 2024, to regain compliance.
To regain compliance, MVLS must equal or exceed $50M for at least ten consecutive business days.
If not compliant by deadline, Nasdaq will initiate delisting; company may appeal or transfer to Nasdaq Capital Market.
No immediate effect on listing or trading of common stock on Nasdaq Global Market.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.82

BIORA THERAPEUTICS, INC. received a nasdaq delisting notice notice regarding market value (rules 5450(b)(2)(A), 5810(c)(3)(C)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: market value
Rules: 5450(b)(2)(A), 5810(c)(3)(C)

Exact text from the filing

June 10, 2024 (the “Compliance Date”), to regain compliance with the MVLS Rule. To regain compliance with the MVLS Rule, the Company’s MVLS must equal or exceed $50 million for a minimum of ten consecutive business days at any time prior to the Compliance Date. If the Company regains compliance with the MVLS Rule, Nasdaq will provide the Company with written confirmation and will close the matter. In the event that the Company does not regain compliance with the MVLS Rule by the Compliance Date, it will receive written notification that its securities are subject to delisting. At that time, th

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001193125-23-296812

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.